TORONTO, June 18, 2025 (GLOBE NEWSWIRE) -- Conavi Medical Corp. (TSXV: CNVI) (OTCQB: CNVIF) ("Conavi Medical" or the "Company"), is pleased to invite investors and other interested parties to attend the Company's upcoming live webinar presentation, audience Q&A and interview. CEO Tom Looby will discuss Conavi's unique and market-leading imaging technology for minimally invasive cardiovascular procedures. The webinar will be a live, interactive online event where attendees can ask the presenters questions in ...

New U.S. intracoronary imaging guidelines from the American College of Cardiology and recent peer-reviewed research strongly validate Novasight’s unique value propositionUpsized $20 million financing led by U.S. institutional investors is expected to fund key value inflection points through planned commercial launch of next-generation Novasight Hybrid™ System in H1 2026U.S. FDA 510(k) submission remains on track for calendar Q3 2025 TORONTO, May 30, 2025 (GLOBE NEWSWIRE) -- Conavi Medical Corp. (TSXV: CNVI) ...

Award recognizes Novasight Hybrid™ System’s significant advance in intracoronary imaging technologyTORONTO, May 08, 2025 (GLOBE NEWSWIRE) -- Conavi Medical Corp. (TSXV: CNVI; OTCQB: CNVIF) (“Conavi Medical” or the “Company”), a medical device company focused on designing, manufacturing, and marketing imaging technologies to guide common minimally invasive cardiovascular procedures, today announced that its Novasight Hybrid™ System (“Novasight”) has been named "Product Innovation of the Year" at the 2025 Min ...